Movicol Schokoladengeschmack

Macrogol 3350, the active ingredient in Movicol Schokoladengeschmack, is an osmotic laxative presented as an oral solution for oral use. It contains electrolytes that help maintain fluid balance while treating constipation, helping resolve faecal impaction, and being employed for bowel preparation before diagnostic procedures in adults and children as prescribed.

GNH USA supplies Movicol Schokoladengeschmack as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and oncology centres worldwide, ensuring quality and regulatory compliance across all markets throughout globally.

Movicol Schokoladengeschmack, an osmotic laxative, is used to manage conditions that involve reduced bowel motility or the need for intestinal cleansing.

- Constipation: softens stool and promotes regular bowel movements. - Faecal impaction: facilitates the breakdown and evacuation of hardened stool masses. - Bowel preparation for diagnostic procedures: clears the intestinal tract to improve visualization during colonoscopy or radiologic imaging.

Common and serious adverse reactions have been reported with osmotic laxatives such as Movicol Schokoladengeschmack.

Common Side Effects: - Abdominal bloating - Nausea - Diarrhea

Serious or Rare Side Effects: - Electrolyte imbalance (e.g., hyponatremia, hypokalemia) - Severe dehydration - Allergic reactions (rash, angioedema, anaphylaxis)

Precautions should be observed when prescribing Movicol Schokoladengeschmack.

- Renal impairment: monitor fluid and electrolyte status closely. - Heart failure: use with caution due to sodium content. - Pregnancy: safety not established; discuss risks with a healthcare professional. - Elderly patients: increased risk of dehydration; ensure adequate fluid intake. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Potential drug interactions may affect safety and efficacy.

Major Interactions (Avoid): - Diuretics: may exacerbate electrolyte loss and dehydration. - Lithium therapy: increased risk of lithium toxicity due to altered sodium balance. - Concurrent use of other osmotic laxatives: risk of excessive fluid loss.

Moderate Interactions (Monitor Closely): - Antacids containing sodium: may increase sodium load. - ACE inhibitors: monitor potassium levels. - NSAIDs: monitor renal function.